Topic: Financials & Profitability
is this public? can be for payer or manufacturer
-
Trump’s Drug-Pricing Ideas Would Cost Taxpayers a Bundle
-
The Drugs at the Heart of Our Pricing Crisis
-
Bottom-Up Pricing Estimate for P-quad
-
Modeling P-quad
-
Who Is Sowing Seeds of Confusion About The QALY?
-
Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead
-
Dissecting PhRMA’s Opposition to H.R. 3 Lower Drug Costs Now Act of 2019
-
Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection
-
Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries
-
Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection